Figures & data
Table 1. Respondent characteristics and treatments received.
‘Thoughts on diagnosis’ (A) and ‘most challenging treatment’ (B) word clouds.
In both word clouds, the size of the individual word relates to the number of times it was used by respondents. (A) Represents the three words used by respondents to describe their feelings upon diagnosis of HCC. Question: which three words best describe your feelings when you learned you had HCC? (B) Represents the treatment patients reported as being the most challenging (not including surgery). Question: excluding surgery – which of the treatments you have received for your liver cancer has been the most challenging?
HCC: Hepatocellular carcinoma.
The number of respondents using different sources of advice/information regarding their HCC diagnosis and treatment, as well as the value of these information sources to those who used them. Question: during your diagnosis or treatment where have you gone for advice or counsel and how useful have you found it?
HCC: Hepatocellular carcinoma.
Comparison of the impact of later stage treatment (TACE, SIRT or sorafenib) on quality of life, which would either have been in a negative or positive direction compared with quality of life before the most recent treatment started. Question: thinking about your present or most recent medical treatment, what has been its effect on your quality of life?
SIRT: Selective internal radiation therapy; TACE: Transarterial chemoembolization.
Comparison of proportion of respondents whose late stage treatment (TACE, SIRT or sorafenib) related side effects had a ‘moderate-to-significant’ negative impact on their quality of life.
SIRT: Selective internal radiation therapy; TACE: Transarterial chemoembolization.
Comparison of respondents’ current quality of life rating for those using late-stage treatments (TACE, SIRT or sorafenib). Question: how would you rate your quality of life today?
SIRT: Selective internal radiation therapy; TACE: Transarterial chemoembolization.
